Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Current Deferred Revenue for 3 consecutive years, with $669996.8 the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Revenue rose 23.88% year-over-year to $669996.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $669996.8 (up 23.88% YoY) and the FY2025 annual result came in at $680000.0, up 42.56% from the prior year.
• Current Deferred Revenue declined to $669996.8 in Q4 2025 per ZYBT's latest filing, from $698000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for ZYBT reached as high as $698000.0 in Q2 2025 and fell as low as $540853.1 in Q4 2024.
• A 3-year average of $636967.7 and a median of $654508.9 in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue decreased 15.36% — and 2025, when it advanced 23.88%.
• Year by year, Current Deferred Revenue stood at $639020.9 in 2023, then dropped by 15.36% to $540853.1 in 2024, then advanced by 23.88% to $669996.8 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $669996.8, $698000.0, and $540853.1 for Q4 2025, Q2 2025, and Q4 2024 respectively.